EP Patent

EP3317281A1 — Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Assigned to Acerta Pharma BV · Expires 2018-05-09 · 8y expired

What this patent protects

In some embodiments, the invention relates to crystalline solid forms, including polymorphs, hydrates, and salt forms, of( S )-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-α]pyrazin-l-yl)- N -(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to…

USPTO Abstract

In some embodiments, the invention relates to crystalline solid forms, including polymorphs, hydrates, and salt forms, of( S )-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-α]pyrazin-l-yl)- N -(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the crystalline solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents. Formula (I)

Drugs covered by this patent

Patent Metadata

Patent number
EP3317281A1
Jurisdiction
EP
Classification
—
Expires
2018-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Acerta Pharma BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.